IBIOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:59):

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States...

Stats
本日の出来高	60 203.00
平均出来高	3.90M
時価総額	14.99M
EPS	$0 ( 2024-02-13 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0110 (0.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Duran Felipe	Buy	35 800	Stock Option (right to buy)
2023-11-01	Brenner Martin	Sell	4 881	Common Stock
2023-10-03	Brenner Martin	Sell	5 267	Common Stock
2023-10-02	Brenner Martin	Sell	4 215	Common Stock
2023-08-28	Brenner Martin	Sell	5 011	Common Stock

INSIDER POWER
85.87
Last 90 transactions
Buy: 50 021 245 \| Sell: 29 398 433

ボリューム相関

長: -0.22 (neutral)

短: -0.61 (weak negative)

Signal:(48.787) Neutral

Ibio Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ibio Inc 相関 - 通貨/商品

-0.27
( neutral )

-0.57
( weak negative )

0.00
( neutral )

0.51
( weak )

0.56
( weak )

Ibio Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2023
収益:	$0
総利益:	$-1.11M (0.00 %)
EPS:	$-47.87

FY	2022
収益:	$2.38M
総利益:	$2.17M (90.94 %)
EPS:	$-2 924.26

FY	2021
収益:	$2.37M
総利益:	$909 000 (38.34 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Ibio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.